RESEARCH ARTICLE

Identification of Two Missense Mutations of ERCC6 in Three Chinese Sisters with Cockayne Syndrome by Whole Exome Sequencing

Shanshan Yu¹*, Liyuan Chen²*, Lili Ye¹, Lingna Fei¹, Wei Tang¹, Yujiao Tian¹, Qian Geng², Xin Yi¹*, Jiansheng Xie²*

1. BGI-shenzhen, Shenzhen, 518083, China, 2. Prenatal Diagnosis Center, Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, 518048, China

*jsxie2007@hotmail.com (JX); yix@genomics.cn (XY)

These authors contributed equally to this work.

Abstract

Cockayne syndrome (CS) is a rare autosomal recessive disorder, the primary manifestations of which are poor growth and neurologic abnormality. Mutations of the ERCC6 and ERCC8 genes are the predominant cause of Cockayne syndrome, and the ERCC6 gene mutation is present in approximately 65% of cases. The present report describes a case of Cockayne syndrome in a Chinese family, with the patients carrying two missense mutations (c.1595A>G, p.Asp532Gly and c.1607T>G, p.Leu536Trp) in the ERCC6 gene in an apparently compound heterozygote status, especially, p.Asp532Gly has never been reported. The compound heterozygote mutation was found in three patients in the family using whole exome sequencing. The patients' father and mother carried a heterozygous allele at different locations of the ERCC6 gene, which was confirmed by Sanger DNA sequencing. The two mutations are both located in the highly conserved motif I of ATP-binding helicase and are considered “Damaging,” “Probably Damaging,” “Disease Causing,” and “Conserved”, indicating the role of DNA damage in the pathogenetic process of the disease. The results not only enrich the ERCC6 mutations database, but also indicate that whole exome sequencing will be a powerful tool for discovering the disease causing mutations in clinical diagnosis.
Introduction

Cockayne syndrome (CS; MIM 216400, 133540) is a rare autosomal recessive neurodegenerative disorder characterized by progressive growth failure, microcephaly, mental retardation, retinal pigmented degeneration, deafness, photosensitivity, accelerated systemic degeneration of somatic tissue and premature death. Cockayne syndrome spans a phenotypic spectrum that includes CS type I, CS type II, CS type III, and Xeroderma pigmentosum-Cockayne syndrome (XP-CS). Due to the wide clinical variability, the diagnosis of this disorder is quite difficult during early stages. Molecular genetic testing can confirm the diagnosis. Mutations in the ERCC6 and ERCC8 genes are known to cause Cockayne syndrome [1–4] and approximately 65% individuals with CS have mutations in the ERCC6 gene [5].

The ERCC6 gene is located on chromosome 10q11.23, encoding a protein belonging to the SWI2/SNF2 family that contains an acidic domain, a glycine-rich region, two putative nuclear localized signal sequences, and seven characteristic helicase ATPase domains. It is part of the nucleotide excision repair (NER) pathway, a complex system that eliminates a broad spectrum of structural DNA lesions, including ultraviolet (UV)-induced cyclobutane pyrimidine dimers, bulky chemical adducts, and DNA cross-links. One of the NER pathways preferentially repairs lesions on the transcribed strand of active genes; this process occurs more rapidly than repairs on nontranscribed strands, which is part of overall genome repair [6].

The present study reports two ERCC6 mutations identified by whole exome sequencing in three individuals with Cockayne syndrome from a Chinese family. The two missense mutations are c.1595A>G and c.1607T>G, which are located in exon 7 of the ERCC6 gene, and the c.1595A>G has never been reported.

Materials and Methods

Samples collection

We collected a 5 ml peripheral blood sample from each person in the family.

Ethics statement

The study was conducted in accordance with the guiding principles of the Declaration of Helsinki. Collection of samples was approved by the ethical committees of Shenzhen Maternity and Child Healthcare Hospital, and informed written consent was obtained from the parents of the three affected sisters because the sisters did not have the capacity to understand and sign written informed consent. The parents completely understood that their peripheral blood samples would be used in this research and requested genetic counseling. We followed all regulations for the enrollment of patients, sample collection and informed consent for the purpose of research. All studies using human materials in this article were
approved by the ethical committee of Shenzhen Maternity and Child Healthcare Hospital.

Clinical report
The three affected individuals with Cockayne syndrome are sisters from a Chinese family (Fig. 1A). Their parents are nonconsanguineous and healthy. The three sisters were all born at full-term by vaginal delivery and had no abnormalities at birth. They had similar clinical features including postnatal growth failure, severe and progressive neurological deterioration, cachexia, and photosensitivity (Fig. 2A). The major clinical manifestations of the three sisters are summarized in Table 1. The results of laboratory tests for the proband (II1) were as follows: normal karyotype (46, XX); no subtelomeric duplications or deletions in any chromosomes, as detected by P036 and P070 Multiplex Ligation Dependent Probe Amplification (MLPA) kits (MRC-Holland, Netherlands); no microdeletion syndromes, as detected with a P245 MLPA kit (MRC-Holland, Netherlands); absence of clinically significant microdeletions and microduplications, as detected using a Array-CGH (Comparative genomic hybridization) Agilent 180K chip (Agilent, USA); and no inherited metabolic diseases, as detected by tandem mass spectrometric analysis. The cerebra MR imaging for the proband showed signs of hypomyelination (Fig. 2B). The brain CT scan showed that calcification on bilateral globus pallidus, cerebral atrophy (widened sulcus and cleft, enlarged superatentorial ventricle, narrowed gyrus) (Fig. 2C).

Exome capture and next-generation sequencing
Genomic DNA was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The genomic DNA of the three patients was then fragmented by Covaris S2 (Massachusetts, USA) to generate 200–300bp insert fragments. The paired-end libraries were prepared following Illumina library preparation the protocol. Exome capture was performed to collect the whole exons of the human genomic DNA using an Agilent SureSelect Human All Exon Plus kit (44 Mb Kit, Agilent Technology, Inc.). The exon-enriched DNA libraries were sequenced by 100 bp paired-end reads on a Hiseq2000 sequencer (Illumina, San Diego, California). Raw image files were processed by the Illumina Pipeline for base calling using default parameters.

Reads mapping and variants analysis
Primary data came in fastq form after image analysis and base calling was conducted using the Illumina Pipeline. The data were filtered to generate “clean reads” by removing adapters and low quality reads (<Q20). Sequencing reads were mapped to the reference human genome version hg19 (200902 release, http://genome.ucsc.edu/) using the BWA (Burrows Wheeler Aligner) Multi-Vision software package. Variant analysis was performed using SOAPsnp software
and Samtools for SNPs and indels, respectively. All SNPs were identified using the NCBI dbSNP137, HapMap, 1000 human genome dataset (20110521 release, http://www.1000genomes.org/) and a local database of 100 Chinese healthy adults.

Sanger sequencing

Sanger sequencing was performed to confirm the two variants of the ERCC6 gene found by exome sequencing. We amplified the target sites and the flanking sequences of the DNA template of each family member individually with specific primers designed using Primer5.0 (forward primer 5’-CTGCCCTACAGCTCCATT-3’ and reverse primer 5’-TCCACCATTTGCCATTTT-3’). PCR amplification was carried out in an ABI 9700 Thermal Cycler using standard conditions. PCR conditions were as follows: an initial denaturation step at 95°C for 5 min, followed by 94°C for 30 s, annealing at 55°C for 30 s, and an extension at 72°C for 30 s. A final extension of 72°C for 5 min was performed. After the amplification, products were purified using a Universal DNA Purification Kit (Tiangen) and directly sequenced on an ABI PRISM 3730 automated sequencer (Applied Biosystems). The sequencing results were compared with the annotated ERCC6 gene reference sequence (NC_000010.10) to confirm the candidate nucleotide variants.
Prediction analysis

We used dbNSFP ([http://sites.google.com/site/jpopgen/dbNSFP](http://sites.google.com/site/jpopgen/dbNSFP)) [7], which compiles prediction scores from SIFT, PolyPhen-2, LRT and MutationTaster, along with a conservation score (PhyloP), to predict the pathogenicity of the single-nucleotide substitution variants.

Figure 2. The face photo, skull MRI and CT scan of the proband. A) The face photo of the proband (a, the normal position; b, the lateral position). B) The skull MRI of the proband at 2 years old (a, the plain scanning; b, enhanced scanning). Hyperintensity was seen in centrum semiovale bilaterally, corona radiate, white matter of frontal and parietal lobe, anterior limb of internal capsule, external capsule in T2 weighted images. T2 weighted images show less low signal in the posterior limb of internal capsule. C) The brain CT scan shown that calcification on bilateral globus pallidus, cerebral atrophy (widened sulcus and cleft, enlarged superatentorial ventricle, narrowed gyrus).

doi:10.1371/journal.pone.0113914.g002
In addition, SWISS-Model Repository [http://swissmodel.expasy.org/repository/] [8] and PROSITE [http://www.expasy.org/prosite/] [9] were used to analyze the protein structure, conservation domain and functional domain.

### Results

#### Exome Sequencing

We sequenced the exome of three affected individuals from the same family (Samples II-1, II-2 and II-3, Fig. 1A). We generated an average of 103.52 million reads of sequence with 128.87-fold average coverage for all affected individuals as paired-end, 90 bp reads. Approximately 99.22% of the reads passed the quality assessment and aligned to the human reference genome 19, and approximately 98.9% of the targeted bases were sufficiently covered to pass our thresholds for calling SNPs and InDels (Table S1).

| Patients          | II1                                      | II2                                      | II3                                      |
|-------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| Gestational age   | Full-term vaginal delivery               | Full-term vaginal delivery               | Full-term vaginal delivery               |
| Birth weight      | 2.51 kg                                  | 2.50 kg                                  | 2.50 kg                                  |
| Age at clinic visit | 4 years and 8 months                     | 3 years and 5 months                     | 1 year and 9 months                      |
| Gesell developmental scales | developmental age equal to 15 months, developmental quotient 60 | developmental age equal to 18 months, developmental quotient 44 | developmental age equal to 12.5 months, developmental quotient 57 |
| Gross motor       | developmental age equal to 13.8 months, developmental quotient 57 | developmental age equal to 12.8 months, developmental quotient 32 | developmental age equal to 11.8 months, developmental quotient 54 |
| Fine motor        | developmental age equal to 14 months, developmental quotient 64 | developmental age equal to 18 months, developmental quotient 44 | developmental age equal to 14 months, developmental quotient 64 |
| Language          | developmental age equal to 13 months, developmental quotient 56 | developmental age equal to 15.6 months, developmental quotient 38 | developmental age equal to 12.3 months, developmental quotient 56 |
| Social and emotional development | developmental age equal to 14 months, developmental quotient 62 | developmental age equal to 20 months, developmental quotient 49 | developmental age equal to 13.7 months, developmental quotient 62 |
| Physical examination | Height 80 cm (<1th percentile) | 76.5 cm (<1th percentile) | 70 cm (<5th percentile) |
|                   | Weight 9 kg (<1th percentile)            | 7.8 kg (<1th percentile)                 | 8.8 kg (<5th percentile)                 |
|                   | head circumference 44.1 cm (<3th percentile) | 42 cm (<3th percentile)                 | 42.5 cm (<3th percentile)               |

other: pachylosis, deep-set eyes, beaked nose, loss of subcutaneous fat in the face, triangular face with sunburns, dental caries, enamel hypoplasia, malocclusion, muscular atrophy of legs, photosensitive skin rashes with a butterfly distribution in the face, walking unsteady.

In Table S1, we listed the major clinical manifestations of the affected individuals.
According to the criteria mentioned above, we detected more than 80 thousand variants in each patient. After filtering for 364 candidate genes that are related to mental and psychomotor retardation, over 1600 variants were identified in each person. Next, we focused on nonsynonymous (NS) variants, splice acceptor and donor site mutations (SS) and coding indels (Indel) that were relatively more likely to be pathogenic mutations. Because CS is a rare disorder, the causative variants will occur at a very low frequency in the general population. Therefore, we compared the NS/SS/Indel variants against the dbSNP137, HapMap, 1000 human genome dataset and a local database of 100 Chinese healthy adults, and removed the shared SNPs. Given that these patients are related and that they are expected to share the causal variant for CS, we filtered all the detected variations in these patients against each other and found 7 shared variants. And due to the CS in this family is an autosomal recessive inherited disease, we found two SNPs are consistent with AR inherited mode (Table S2). The two SNPs (c.1595A>G, p.Asp532Gly and c.1607T>G, p.Leu536Trp) were compound heterozygous in all three sisters and were located in exon 7 of the ERCC6 gene, which is related to the CS status.

Variant validation by Sanger sequencing
To confirm the accuracy of the mutations identified by exome sequencing, PCR-based Sanger sequencing was performed to analyze the two missense mutations in the three affected sisters and unaffected parents. All three affected individuals carried these compound heterozygous mutations in ERCC6 (c.1607T>G and c.1595A>G), and the unaffected parents carried one of them (Fig. 1B). The cosegregation analysis in this family indicated that the c.1607T>G (p.Leu536Trp) missense mutation was inherited from the unaffected father, and the other mutation (c.1595A>G, p.Asp532Gly) inherited from unaffected mother, consistent with the phenotype of this family. The results showed complete consistency between the exome sequencing and the Sanger sequencing, suggesting that exome sequencing provides high accuracy and can be applied to the analysis of clinical samples.

Prediction analysis
The ERCC6 gene is located at 10q11.23 and encodes a 1493aa protein called excision repair protein (ERCC6). It is also named ATP-dependent helicase ERCC6 or Cockayne syndrome protein (CSB protein). CSB protein contains an ATP-binding domain from residue 519 to residue 695 [10]. This ATP-binding domain is highly conserved in mammals, reptile, nematode, oyster and insects compared with Sus scrofa, Ailuropoda melanoleuca, Canis familiaris, Myotis lucifugus, Equus caballus, Cricetulus griseus, Loxodonta Africana, Mus musculus, Anas platyrhynchos, Crassostrea gigas, Ophiophagus hannah, Ascaris suum, Acromyrmex echinatior and Heliconius erato (Fig. 3A). The structure of the CSB protein is shown in Fig. 3B. It contains two essential components: ATPase and Ubiquitin binding domain [11].
The two mutations D532G and L536W are located immediately in motif I of the ATPase domain (Fig. 3B), and have been characterized as “Damaging,” “Probably Damaging,” “Disease-causing,” “Conserved” and “NA” using SIFT, Polyphen2, MutationTaster, PhyloP and LRT, respectively. In addition, these two mutations were detected in another 105 Chinese individuals (63 healthy controls and 42 patients of other disease), but none of them had both mutations. All of these results indicate that those two mutations are the most probable cause of Cockayne’s syndrome.

Discussion

Cockayne’s syndrome (CS) is a rare autosomal recessive disorder that results in postnatal growth failure, microcephaly, sensorial impairment, cutaneous photosensitivity, recognizable facial appearance with deep sunken eyes and progressive neurologic dysfunction, most symptoms appear and worsen with time. This disorder is classified as a segmental progeria that arises due to a mutation in
In previous studies, short insertions and deletions, nonsense mutations, splice mutations, missense mutations and promoter mutation have all been implicated in Cockayne’s syndrome, and among the 84 reported cases up to 2009, approximate 65% had mutations in the **ERCC6** [5, 12]. A classic Cockayne’s syndrome case has been reported carrying a novel homozygous nonsense mutation c.1387C>T/Q463X in the **ERCC6** gene [13]. Another report identified two novel **ERCC6** mutations (a splice-site mutation, c.2709+1G>T, in intron 14 and a short deletion in exon 5 (c.1293_1320del) in an Amish individual with Cockayne’s syndrome [14].

In the present study, we performed exome sequencing for genetic testing of three sisters with postnatal growth failure and neurological impairment using the Hiseq2000 platform. After exome sequencing analysis and criteria filtering, we identified two missense mutations in the **ERCC6** gene in the three affected sisters. The c.1595A>G missense mutation results in the substitution of aspartic acid (D) for glycine (G) at residue 532, which has never been reported. The c.1607T>G missense mutation results in the substitution of leucine (L) for tryptophan (W) at residue 536 that had been recorded but no details [15]. The Sanger sequencing and co-segregation analysis in this family indicated that the compound heterozygous c.1595A>G and c.1607T>G mutations in the three affected sisters were inherited from their unaffected father and mother, respectively, consistent with the phenotypes of these family members. Additionally, the c.1595A>G missense mutation and the c.1607T>G missense mutation are predicted to be “Damaging” and “Probably damaging”, respectively, by SIFT and PolyPhen-2, and both are located in the highly conserved motif I of ATP-binding helicase.

The **ERCC6** gene encompasses 21 exons and yields an 8993 bp transcript that encodes the 1493aa CSB protein. It is a component of the nucleotide excision repair (NER) pathway, a complex system that eliminates a broad spectrum of structural DNA lesions, including ultraviolet (UV)-induced cyclobutane pyrimidine dimers, bulky chemical adducts, and DNA cross-links [16, 17]. The cellular roles played by the CSB protein in repair, transcription, chromatin remodeling and apoptosis may be mediated by distinct functional domains of the protein [18]. The conserved helicase ATPase has been shown to be an essential functional domain of the CSB protein in responding to UV-induced DNA damage in previous studies [19–21]. Furthermore, other studies have suggested that the recruitment of CSB to lesion-stalled transcription and chromatin remodeling is an ATP-dependent process [22]. Evidence indicates that the integrity of the motif I and II are important for CSB function. A point mutation in ATPase motif I of CSB rendered the protein totally defective in ATP hydrolysis, but it was still able to partially rescue the delay in RNA synthesis recovery after exposure to UV light when microinjected into an immortalized human CS-B fibroblast cell line [23]. A point mutation in motif II of the ATPase domain completely abolished the ability of CSB to function in survival, RNA synthesis recovery, gene-specific repair and apoptosis upon UV irradiation in hamster and human cells [24, 25]. And other study demonstrated the point mutations in ATPase motif Ia, III, V and VI also abolished the genetic function of the CSB protein in survival, RNA synthesis
recovery and apoptosis after UV treatment [18]. Therefore, the two missense mutations, D532G and L536W, located in the motif I of ATP-Binding domain loss of ATP hydrolysis and then fail to repair the DNA damage which maybe the pathogenic reason of the three sisters.

In summary, we have described three Chinese sisters with Cockayne’s syndrome. Exome sequencing was performed, identifying two missense mutations p.Asp532Gly that is never been reported and p.Leu536Trp in the ERCC6 gene. The results not only enrich the known mutation spectrum of this DNA repair disorder, but also indicate that whole exome sequencing will be a powerful tool for discovering the disease causing mutations in clinical diagnosis.

Supporting Information

Table S1. Summary of exome sequencing data.
doi:10.1371/journal.pone.0113914.s001 (DOCX)

Table S2. Candidate genetic variants identified.
doi:10.1371/journal.pone.0113914.s002 (DOCX)

Author Contributions

Conceived and designed the experiments: SY XY JX. Performed the experiments: LC LY LF YT QG. Analyzed the data: WT. Contributed reagents/materials/analysis tools: XY JX. Wrote the paper: SY LC LY LF YT QG XY JX.

References

1. Nance MA, Berry SA (1992) Cockayne syndrome: review of 140 cases. Am J Med Genet 42: 68–84.
2. Bootsma D, Weeda G, Vermeulen W, van Vuuren H, Troelstra C, et al. (1995) Nucleotide excision repair syndromes: molecular basis and clinical symptoms. Philos Trans R Soc Lond B Biol Sci 30: 75–81.
3. Henning KA, Li L, Iyer N, McDaniel LD, Reagan MS, et al. (1995) The Cockayne syndrome group A gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH. Cell 82: 555–564.
4. Pasquier L, Laugel V, Lazaro L, Dolfus H, Journel H, et al. (2006) Wide clinical variability among 13 new Cockayne syndrome cases confirmed by biochemical assays. Arch Dis Child 91: 178–182.
5. Laugel V, Dalloz C, Durand M, Sauvanaud F, Kristensen U, et al. (2010) Mutation Update for the CSB/ERCC6 and CSA/ERCC8 Genes Involved in Cockayne Syndrome. Hum Mutat 31: 113–126.
6. Troelstra C, van Gool A, de Wit J, Vermeulen W, Bootsma D, et al. (1992) ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne’s syndrome and preferential repair of active genes. Cell 71: 939–953.
7. Liu X, Jian X, Boerwinkle E (2011) dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. Hum Mutat 32: 894–899.
8. Kiefer F, Arnold K, Künzli M, Bordoli L, Schwede T (2009) The SWISS-MODEL Repository and associated resources. Nucleic Acids Res 37: D387–D392.
9. Sigrist CJ, de Castro E, Cerutti L, Cuche BA, Hulo N, et al. (2012) New and continuing developments at PROSITE. Nucleic Acids Res 41: D344–D347.
10. Anindya R, Mari PO, Kristensen U, Kool H, Giglia-Mari G, et al. (2010) A Ubiquitin-Binding Domain in Cockayne Syndrome B Required for Transcription-Coupled Nucleotide Excision Repair. Molecular Cell 38: 637–648.

11. Ren J, Wen L, Gao X, Jin C, Xue Y, et al. (2009) DOG 1.0 Illustrator of Protein Domain Structure. Cell Research 19: 271–273.

12. Mallery DL, Tanganelli B, Colella S, Steingrimsdottir H, van Gool AJ, et al. (1998) Molecular Analysis of Mutations in the CSB (ERCC6) Gene in Patients with Cockayne Syndrome. Am J Hum Genet 62: 77–85.

13. Zhang H, Gao J, Ye J, Gong Z, Gu X (2011) Maternal origin of a de novo microdeletion spanning the ERCC6 gene in a classic form of the Cockayne syndrome. Eur J Med Genet 54: e389–393.

14. Xin B, Wang H (2013) Identification of Two Novel ERCC6 Mutations in Old Order Amish with Cockayne Syndrome. Mol Syndromol 3: 288–290.

15. Laugel V (2013) Cockayne syndrome: The expanding clinical and mutational spectrum. Mech Ageing Dev 134(5–6): 161–170.

16. Proietti-De-Santis L, Drane P, Egly JM (2006) Cockayne syndrome B protein regulates the transcriptional program after UV irradiation. EMBO J 25: 1915–1923.

17. Vélez-Cruz R, Egly JM (2013) Cockayne syndrome group B (CSB) protein: At the crossroads of transcriptional networks. Mech Ageing Dev 134: 234–242.

18. Muftuoglu M, Selzer R, Tuo J, Brosh RM Jr, Bohr VA (2002) Phenotypic consequences of mutations in the conserved motifs of the putative helicase domain of the human Cockayne syndrome group B gene. Gene 283(1–2): 27–40.

19. Brosh RM Jr, Balajee AS, Selzer RR, Sunesen M, Proietti De Santis L, et al. (1999) The ATPase Domain but Not the Acidic Region of Cockayne Syndrome Group B Gene Product Is Essential for DNA Repair. Mol Biol Cell 10: 3583–3594.

20. Selzer RR, Nyaga S, Tuo J, May A, Muftuoglu M, et al. (2002) Differential requirement for the ATPase domain of the Cockayne syndrome group B gene in the processing of UV-induced DNA damage and 8-oxoguanine lesions in human cells. Nucleic Acids Res 30: 782–793.

21. Cho I, Tsai PF, Lake RJ, Basheer A, Fan HY (2013) ATP-Dependent Chromatin Remodeling by Cockayne Syndrome Protein B and NAP1-Like Histone Chaperones Is Required for Efficient Transcription-Coupled DNA Repair. PLoS Genet 9: e1003407.

22. Lake RJ, Geyko A, Hemashettar G, Zhao Y, Fan HY (2010) UV-induced association of the CSB remodeling protein with chromatin requires ATP-dependent relief of N-terminal autorepression. Mol Cell 37: 235–246.

23. Citterio E, Rademaker S, van der Horst GT, van Gool A, Hoeijmakers HJ, et al. (1998) Biochemical and biological characterization of wild type and ATPase-deficient Cockayne syndrome B repair protein. J Biol Chem 273: 11844–11852.

24. Brosh RM Jr, Balajee AS, Selzer RR, Sunesen M, De Santis LP, et al. (1999) The ATPase domain but not the acidic region of Cockayne syndrome group B gene product is essential for DNA repair. Mol Biol Cell 10: 3583–3594.

25. Selzer RR, Nyaga S, Tuo J, May A, Muftuoglu M, et al. (2002) Differential requirement for the ATPase domain of the Cockayne syndrome group B gene in the processing of UV-induced DNA damage and 8-oxoguanine lesions in human cells. Nucleic Acids Res 30: 782–793.